Description
Indication & Scope
ZePuPing® Gecacitinib Hydrochloride Tablets treats adult patients with intermediate or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), and post-essential thrombocythemia myelofibrosis (PET-MF).
- Mechanism: Selective oral JAK1/JAK2 dual kinase inhibitor, blocks abnormal JAK-STAT hyperactivated signaling in myeloproliferative neoplasms, reduces splenomegaly and alleviates systemic inflammatory myelofibrosis symptoms including fatigue, bone pain and night sweats.
- Drug class: Oral JAK1/JAK2 inhibitor, myeloproliferative disorder targeted prescription small-molecule medicine.
- Clinical use: First-line disease-modifying therapy for intermediate and high-risk myelofibrosis subtypes to control splenomegaly and constitutional symptoms.
| Generic Name | Gecacitinib Hydrochloride Tablets |
| Brand Name | ZePuPing |
| Ingredient | Gecacitinib Hydrochloride |
| Dosage Form | Tablets |
| Package | 50mg*60 tablets/box |
| Conditions Treated | Primary myelofibrosis, post-PV myelofibrosis, post-ET myelofibrosis in adult patients |
| Taboos | Severe hypersensitivity to gecacitinib hydrochloride; patients with active severe bacterial/viral infection; pregnant women |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Sealed storage below 25°C, light and moisture resistant |
| Manufacturer | ZeJing Biophamaceutical Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20250021 |
| Approval Date | May 27, 2025 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: Weight and risk-stratified once-daily oral continuous dose.
Time: Same fixed daily dosing time for lifelong continuous treatment until intolerable toxicity.
Instructions for use: Tablets swallowed whole, may be taken with food; regular monitoring of complete blood counts and liver function monthly.
Interaction: Strong CYP3A4 modulators alter systemic drug levels, dose adjustment is mandatory for combined use.
Side effects: Anemia, thrombocytopenia, fatigue, diarrhea, elevated liver enzymes, upper respiratory tract infections.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What diseases does Gecacitinib Hydrochloride Tablets treat?
It treats primary myelofibrosis and secondary myelofibrosis after polycythemia vera and thrombocythemia.
What is Gecacitinib Hydrochloride Tablets' pharmacological classification?
It is a dual JAK1/JAK2 oral inhibitor for myeloproliferative neoplasms.
What core symptoms can Gecacitinib Hydrochloride Tablets improve?
It reduces splenomegaly and relieves constitutional symptoms such as fatigue, night sweats and bone pain.
What routine monitoring is required during medication of Gecacitinib Hydrochloride Tablets?
Monthly blood routine and liver function tests are necessary to avoid hematological and hepatic toxicity.
ZePuPing® | Gecacitinib Hydrochloride Tablets | PMF/PPV-MF/PET-MF | DengYueRX
INN: Gecacitinib Hydrochloride Tablets
Indications: PMF/PPV-MF/PET-MF
Dosage Form: Tablets
Strength: 50mg/tablet
Low MOQ
WHO-GMP
Worldwide Delivery
Compliance and Regulatory Documents
Related Products
